Oncoinvent Announces Promising Interim Results for Radspherin® in Peritoneal Carcinomatosis Treatment

Oncoinvent ASA, a clinical-stage company developing alpha emitter therapies for solid cancers, today reported interim data from the Phase 1/2a trials of Radspherin® for the treatment of peritoneal carcinomatosis. Recruitment for these studies concluded at the end of 2023, with…

Read MoreOncoinvent Announces Promising Interim Results for Radspherin® in Peritoneal Carcinomatosis Treatment

Novotech Wins 2024 Clinical Trials Arena Excellence Award for Business Development and Innovation

Novotech, a full-service global contract research organization (CRO), has been honored with multiple awards at the 2024 Clinical Trials Arena Excellence Awards. These prestigious accolades recognize Novotech’s achievements in business development, innovation, and marketing, underscoring the company’s commitment to advancing…

Read MoreNovotech Wins 2024 Clinical Trials Arena Excellence Award for Business Development and Innovation

Mirum Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced that on November 8, 2024, its Compensation Committee granted inducement awards to seven new employees under the company’s 2020 Inducement Plan. These awards consist of non-qualified stock options to purchase 56,100 shares of common…

Read MoreMirum Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)